Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial

BACKGROUND: In a phase 1/2 study, a maternal respiratory syncytial virus vaccine candidate (RSVPreF3) demonstrated an acceptable safety profile and efficiently increased RSV-specific humoral immune responses in non-pregnant women. METHODS: In this phase 2 observer-blind, placebo-controlled, randomiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Bebia, Zourab, Reyes, Osvaldo, Jeanfreau, Robert, Kantele, Anu, De Leon, Ruth Graciela, Sánchez, Marta García, Banooni, Peyman, Gardener, Glenn J, Rasero, José Luis Bartha, Pardilla, Maria Begoña Encinas, Langley, Joanne M, Di Leo, Claudio Maañón, Botelho-Nevers, Elisabeth, Buttery, Jim, Laurichesse, Helene, Madhi, Shabir A, García, Adrián Martín, Stanley, Thorsten, Barjat, Tiphaine, Griffith, Rebecca, Castrejón-Alba, Maria Mercedes, de Heusch, Magali, Dieussaert, Ilse, Hercor, Melanie, Lese, Patricia, Qian, Hui, Tullio, Antonella N, Henry, Ouzama
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10420396/
https://www.ncbi.nlm.nih.gov/pubmed/36722147
http://dx.doi.org/10.1093/infdis/jiad024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10420396/
https://www.ncbi.nlm.nih.gov/pubmed/36722147
http://dx.doi.org/10.1093/infdis/jiad024

Ejemplares similares